Bavarian Association of Statutory Health Insurance Physicians, München, Germany.
Institute of General Practice and Health Services Research, TUM School of Medicine, Technical University Munich, Munich, Germany.
BMJ Open. 2022 Sep 22;12(9):e064979. doi: 10.1136/bmjopen-2022-064979.
To estimate the treatment incidence of post-COVID syndrome (postinfectious sequelae present at least 12 weeks following infection) in the context of ambulatory care in Bavaria, Germany, and to establish whether related diagnoses occur more frequently than in patients with no known history of COVID-19.
Retrospective cohort analysis of routinely collected claims data.
Ambulatory care in Bavaria, Germany, observed from January 2020 to March 2022 (data accessed May 2022).
391 990 patients with confirmed COVID-19 diagnosis, 62 659 patients with other respiratory infection and a control group of 659 579 patients with no confirmed or suspected diagnosis of COVID-19.
Primary outcome is diagnosis of post-COVID syndrome documented in ambulatory care. Secondary outcomes are: chronic fatigue syndrome, psychological disorder, fatigue, mild cognitive impairment, disturbances of taste and smell, dyspnoea, pulmonary embolism and myalgia.
Among all patients with confirmed COVID-19, 14.2% (95% CI 14.0% to 14.5%) received a diagnosis of a post-COVID syndrome, and 6.7% (95% CI 6.5% to 6.9%) received the diagnosis in at least two quarterly periods during a 2-year follow-up. Compared with patients with other respiratory infections and with controls, patients with COVID-19 more frequently received a variety of diagnoses including chronic fatigue syndrome (1.6% vs 0.6% and 0.3%, respectively), fatigue (13.3% vs 9.2% and 6.0%), dyspnoea (9.9% vs 5.1% and 3.2%) and disturbances of taste and smell (3.2% vs 1.2% and 0.5%). The treatment incidence of post-COVID syndrome was highest among adults aged 40-59 (19.0%) and lowest among children aged below 12 years (2.6%).
Our results demonstrate a moderately high incidence of post-COVID syndrome 2 years after COVID-19 diagnosis. There is an urgent need to find efficient and effective solutions to help patients with dyspnoea, fatigue, cognitive impairment and loss of smell. Guidelines and treatment algorithms, including referral criteria, and occupational and physical therapy, require prompt and coherent implementation.
估计德国巴伐利亚州门诊环境中新冠后综合征(感染后至少 12 周仍存在的后遗症)的治疗发生率,并确定与无已知新冠病史的患者相比,相关诊断是否更频繁。
回顾性队列分析常规收集的索赔数据。
德国巴伐利亚州门诊环境,观察时间为 2020 年 1 月至 2022 年 3 月(数据于 2022 年 5 月获取)。
391990 名确诊新冠的患者、62659 名患有其他呼吸道感染的患者和 659579 名无确诊或疑似新冠诊断的对照组患者。
主要结局是门诊确诊新冠后综合征的诊断。次要结局是慢性疲劳综合征、心理障碍、疲劳、轻度认知障碍、味觉和嗅觉障碍、呼吸困难、肺栓塞和肌痛。
在所有确诊新冠的患者中,14.2%(95%置信区间 14.0%至 14.5%)被诊断为新冠后综合征,6.7%(95%置信区间 6.5%至 6.9%)在 2 年随访期间至少在两个季度内被诊断出该疾病。与其他呼吸道感染和对照组患者相比,新冠患者更频繁地接受各种诊断,包括慢性疲劳综合征(1.6%比 0.6%和 0.3%)、疲劳(13.3%比 9.2%和 6.0%)、呼吸困难(9.9%比 5.1%和 3.2%)和味觉和嗅觉障碍(3.2%比 1.2%和 0.5%)。40-59 岁成人的新冠后综合征治疗发生率最高(19.0%),12 岁以下儿童最低(2.6%)。
我们的结果表明,新冠确诊后 2 年新冠后综合征的发生率较高。迫切需要找到有效和有效的解决方案来帮助呼吸困难、疲劳、认知障碍和嗅觉丧失的患者。指南和治疗算法,包括转诊标准以及职业和物理治疗,需要及时和一致地实施。